Activity of LCB01-0371, a Novel Oxazolidinone, against Mycobacterium abscessus
- Authors
- Kim, Tae Sung; Choe, Jin Ho; Kim, Young Jae; Yang, Chul-Su; Kwon, Hyun-Jin; Jeong, Jinsun; Kim, Guehye; Park, Da Eun; Jo, Eun-Kyeong; Cho, Young-Lag; Jang, Jichan
- Issue Date
- Sep-2017
- Publisher
- American Society for Microbiology
- Keywords
- drug resistance; LCB01-0371; Mycobacterium abscessus; oxazolidinone
- Citation
- Antimicrobial Agents and Chemotherapy, v.61, no.9, pp 1 - 12
- Pages
- 12
- Indexed
- SCI
SCIE
SCOPUS
- Journal Title
- Antimicrobial Agents and Chemotherapy
- Volume
- 61
- Number
- 9
- Start Page
- 1
- End Page
- 12
- URI
- https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/9023
- DOI
- 10.1128/AAC.02752-16
- ISSN
- 0066-4804
1098-6596
- Abstract
- Mycobacterium abscessus is a highly pathogenic drug-resistant rapidly growing mycobacterium. In this study, we evaluated the in vitro, intracellular, and in vivo activities of LCB01-0371, a novel and safe oxazolidinone derivative, for the treatment of M. abscessus infection and compared its resistance to that of other oxazolidinone drugs. LCB01-0371 was effective against several M. abscessus strains in vitro and in a macrophage model of infection. In the murine model, a similar efficacy to linezolid was achieved, especially in the lungs. We induced laboratory-generated resistance to LCB01-0371; sequencing analysis revealed mutations in rplC of T424C and G419A and a nucleotide insertion at the 503 position. Furthermore, LCB01-0371 inhibited the growth of amikacin-, cefoxitin-, and clarithromycin-resistant strains. Collectively, our data indicate that LCB01-0371 might represent a promising new class of oxazolidinones with improved safety, which may replace linezolid for the treatment of M. abscessus.
- Files in This Item
-
Go to Link
- Appears in
Collections - COLLEGE OF SCIENCE AND CONVERGENCE TECHNOLOGY > ERICA 의약생명과학과 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.